Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Clinical Trials

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-10-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 155

Registration Number: NCT01107912

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden

Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: prasugrel
Drug: clopidogrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-08-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT01107925

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Phase 1

Terminated

Conditions: Acute Coronary Syndromes

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT01107899

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany

The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

Phase 4

Completed

Conditions: Healthy Volunteers
Sepsis

Interventions: Drug: Placebo
Drug: Prasugrel

First Posted Date: 2010-04-07

Last Posted Date: 2011-07-11

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 20

Registration Number: NCT01099566

Locations: 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

Phase 3

Completed

Conditions: Acute Coronary Syndromes

Interventions: Drug: Placebo
Drug: Prasugrel

First Posted Date: 2009-11-18

Last Posted Date: 2014-02-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4033

Registration Number: NCT01015287

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sisli, Turkey

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2009-11-17

Last Posted Date: 2021-06-28

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 56

Registration Number: NCT01014624

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸
Black Hills Clinical Research Center, Rapid City, South Dakota, United States
🇺🇸
University of Florida Health Science Center Shands Jacksonville, Jacksonville, Florida, United States

and more 1 locations

TAXUS Libertē Post Approval Study

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2009-10-19

Last Posted Date: 2015-08-07

Lead Sponsor: Boston Scientific Corporation

Target Recruit Count: 4199

Registration Number: NCT00997503

Locations: 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇺🇸
Advanced Cardiac Specialists, Mesa, Arizona, United States
🇺🇸
NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States

and more 79 locations

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2009-09-14

Last Posted Date: 2014-01-07

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 548

Registration Number: NCT00976092

Locations: 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Bavaria, Germany
🇩🇪
Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Bavaria, Germany
🇩🇪
Herzzentrum der Segeberger Kliniken, Bad Segeberg, Germany

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Phase 2

Terminated

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2009-05-29

Last Posted Date: 2012-06-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 423

Registration Number: NCT00910299

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2009-01-28

Last Posted Date: 2011-11-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 720

Registration Number: NCT00830960

Locations: 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiang Mai, Thailand

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy